Abstract | PURPOSE: This prospective pilot single-institution study was undertaken to document the feasibility, safety, and efficacy of treatment of liver-dominant metastatic gastrointestinal cancer using (90)Y glass microspheres. METHODS: Between June 2010 and November 2012, 30 adult patients (22 men, eight women; median age 61 years) with metastatic chemotherapy-refractory unresectable colorectal (n = 15), neuroendocrine (n = 9), intrahepatic cholangiocarcinoma (n = 3), pancreas (n = 2), and esophageal (n = 1) carcinomas underwent 45 lobar or segmental administrations of (90)Y glass microspheres. Data regarding clinical and laboratory adverse events (AE) were collected prospectively for 6 months after each treatment. Radiographic responses were evaluated using Response Evaluation Criteria in Solid Tumors, version 1.1. Time to maximum response, response duration, progression-free survival (hepatic and extrahepatic), and overall survival were measured. RESULTS: Median target dose and activity were 111.6 Gy and 2.5 GBq per treatment session, respectively. All but three clinical AE were grade 1 or 2 in severity. Serious AE included an unplanned hospital admission for carcinoid crisis, grade 3 vomiting, and grade 4 gastric ulcer. Patients with colorectal cancer had hepatic objective response rate (ORR) of 27 % and a disease control rate (DCR) of 73 %. Median progression-free and overall survival were 1.0 and 4.9 months, respectively. Patients with neuroendocrine tumors had hepatic ORR and DCR of 78 % and 100 %, respectively. Median progression-free survival was 18.5 months for this cohort. CONCLUSIONS: Y glass microspheres device has a favorable safety profile and achieved prolonged disease control of hepatic tumor burden in a subset of patients, including all patients enrolled in the neuroendocrine cohort.
|
Authors | Nicholas Fidelman, Robert K Kerlan Jr, Randall A Hawkins, Andrew G Taylor, Maureen P Kohi, K Pallav Kolli, Emily K Bergsland, R Kate Kelley, Andrew H Ko, W Michael Korn, Ryan M McWhirter, Jennifer Luan, Alan P Venook |
Journal | Journal of gastrointestinal cancer
(J Gastrointest Cancer)
Vol. 45
Issue 2
Pg. 168-80
(Jun 2014)
ISSN: 1941-6636 [Electronic] United States |
PMID | 24448917
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Drug Resistance, Neoplasm
(radiation effects)
- Feasibility Studies
- Female
- Follow-Up Studies
- Gastrointestinal Neoplasms
(drug therapy, pathology, radiotherapy)
- Humans
- Liver Neoplasms
(drug therapy, radiotherapy, secondary)
- Male
- Microspheres
- Middle Aged
- Neoplasm Staging
- Neuroendocrine Tumors
(drug therapy, pathology, radiotherapy)
- Pilot Projects
- Prognosis
- Prospective Studies
- Yttrium Radioisotopes
(therapeutic use)
|